Sterling Martin

Vericel® Corporation

Vericel is a leader in advanced therapies for the sports medicine and severe burn care markets. We have a portfolio of highly innovative advanced cell therapies and specialty biologics that are focused on changing the standard of care for patients with cartilage damage and severe burns. We currently market two autologous cell therapy products and one specialty biologic product in the United States. Developing autologous (patient's own) cell therapies—with integrity Vericel uses rigorous scientific methods to develop novel therapies for the treatment of patients with autologous (patient's own) cells. In addition, personal integrity, team work, collaboration, and innovative technology are the foundations of our work. We seek to practice transparency in our clinical trials and research, and in our relationships with each other, our patients, and the investors who support us.